Abstract
The Pharmaceutical Benefits Scheme (PBS) reform package was announced in 2006 and was designed to save the government significant expenditure on the PBS through mandatory price cuts and price disclosure arrangements for multi-brand products. Perhaps most significantly, the formulary was spilt in two with no linkages between the formularies on either price or therapeutic outcome. This article examines the potential impact of these changes on the PBS and pharmaceutical policy in Australia more broadly.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
